Page Header   Asian Journal of Pharmaceutical Research and Health Care

Gastro-Protection of Atorvastatin in Indomethacin-Induced Ulcer: Role of Tumor Necrosis Factor-Alpha and Prostaglandins


Affiliations

  • Minia University, Department of Pharmacology, Egypt
  • Sina National College for Medical Studies, Department of Pharmacology and Toxicology, Jeddah, Saudi Arabia

Abstract

Using non - steroidal anti - inflammatory drugs as over - the - counter pain - killers may predispose to gastric ulcer as a side effect. The objective of this study is to investigate the possible benefit of a common statin used in hyperlipedemic patients; atorvastatin (AtoR), in ameliorating the ulcerogenic effect of indomethacin (IndoM), and to explore the possible mechanisms involved. AtoR (10 mg/kg/day) was administered orally for 7 days. At day 7, gastric ulcer was induced by a single dose of IndoM (40 mg/kg i.p.), with or without AtoR pre - treatment. IndoM induced gastric ulcer as evident by notable gastric ulceration in histopathological sections compared to normal control. Gastric tissue in rats receiving IndoM showed significantly higher oxidative stress markers as lipid peroxidation represented by increased malondialdehyde (MDA) content, with significant decrease in gastric tissue nitric oxide (NO) a nd prostaglandin E2 (PGE 2 ) levels, as well as reduction in catalase and superoxide dismutase antioxidant enzymatic activities. In addition, IndoM induced inflammatory signs as shown by the significant increase in tumor necrosis factor - alpha (TNF - α) level a ssessed via ELISA. Pre - administration of AtoR significantly decreased ulcer index (16 ± 1) compared to that of IndoM alone (34 ± 2). In addition, AtoR restored normal gastric histological structure and reverted oxidative and inflammatory markers tested. AtoR confers gastro - protection against IndoM - induced ulceration via reducing gastric oxidative stress and increasing gastric NO and PGE 2 levels, as well as decreasing the inflammatory marker; TNF - α.

Keywords

Atorvastatin, Indomethacin, Gastric Ulcer, ProstaglandinE 2 , TNF - α.

Subject Discipline

Pharmacy and Pharmacology

Full Text:

References

Mohamed A. Morsy and Azza A.K. El-Sheikh. Prevention of Gastric Ulcers. In: Peptic Ulcer Disease. Chai J (Ed.), InTech, Croatia, 2011. ISBN 978-953-307-976-9 http://www.intechopen.com/articles/show/title/prevention-of-gastric- ulcers.

Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728-738.

Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2010; 37:173-177.

Abdelwahab SI. Protective mechanism of gallic acid and its novel derivative against ethanol-induced gastric ulcerogenesis: Involvement of immunomodulation markers, Hsp70 and Bcl-2-associated X protein. Int Immunopharmacol. 2013;16:296-305.

Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010; 9:667-674.

El-Moselhy MA, El-Sheikh AA. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomed Pharmacother. 2014; 68:101-110.

El-Moselhy MA, Abdel-Hamid NM, Abdel-Raheim SR. Gastroprotective effect of nicorandil in indomethacin and alcohol-induced acute ulcers. Appl Biochem Biotechnol. 2009; 152:449-459.

Peskar BM, Ehrlich K, Peskar BA. Role of ATP-sensitive potassium channels in prostaglandin-mediated gastroprotection in the rat. J Pharmacol Exp Ther. 2002; 301:969-974.

Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52:302-310.

Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem. 2002; 306:79-82.

Pacifici GM. Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. Paediatr Drugs. 2013; 15:363-376.

Hull MA, Gardner SH, Hawcroft G. Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev. 2003; 29:309-320.

Olaleye SB, Farombi EO. Attenuation of indomethacin- and HCl/ethanol-induced oxidative gastric mucosa damage in rats by kolaviron, a natural biflavonoid of Garcinia kola seed. Phytother Res. 2006; 20:14-20.

Bhattacharya S, Banerjee D, Bauri AK, Chattopadhyay S, Bandyopadhyay SK. Healing property of the Piper betel phenol, allylpyrocatechol against indomethacin-induced stomach ulceration and mechanism of action. World J Gastroenterol. 2007; 13:3705-3713.

Ajeigbe KO, Olaleye SB, Oladejo EO, Olayanju AO. Effect of folic acid supplementation on oxidative gastric mucosa damage and acid secretory response in the rat. Indian J Pharmacol. 2011; 43:578-581.

Morsy MA, El-Moselhy MA. Mechanisms of the protective effects of curcumin against indomethacin-induced gastric ulcer in rats. Pharmacology. 2013; 91:267-274.

Moustafa YM, Khoder DM, El-Awady EE, Zaitone SA. Sildenafil citrate protects against gastric mucosal damage induced by indomethacin in rats. Eur Rev Med Pharmacol Sci. 2013; 17:179-188.

Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012; 18:2147-2160.

Chatterjee A, Chatterjee S, Das S, Saha A, Chattopadhyay S, Bandyopadhyay SK. Ellagic acid facilitates indomethacininduced gastric ulcer healing via COX-2 up-regulation. Acta Biochim Biophys Sin (Shanghai). 2012; 44:565-576.

Moustafa YM, Khoder DM, El-Awady EE, Zaitone SA. Sildenafil citrate protects against gastric mucosal damage induced by indomethacin in rats. Eur Rev Med Pharmacol Sci. 2013; 17:179-188.

Abbas AM, Sakr HF. Effect of selenium and grape seed extract on indomethacin-induced gastric ulcers in rats. J Physiol Biochem. 2013; 69:527-537.

Ozbakis-Dengiz G, Hekimoglu A, Kandemir N, Kurcer Z. Effects of statins in an indomethacin-induced gastric injury model in rats. Turk J Gastroenterol. 2012; 23:456-462.

Guan F, Liu AB, Li G, Yang Z, Sun Y, Yang CS, Ju J. Deleterious effects of high concentrations of (-)- epigallocatechin-3-gallate and atorvastatin in mice with colon inflammation. Nutr Cancer. 2012; 64:847-855.

Amin KA, Abd El-Twab TM. Oxidative markers, nitric oxide and homocysteine alteration in hypercholesterolimic rats: role of atorvastatine and cinnamon. Int J Clin Exp Med. 2009; 2:254-265.

Han L, Li M, Liu Y, Han C, Ye P. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator- activated receptors in rats. Pharmacology. 2012; 89:74-82.

Pathak NN, Balaganur V, Lingaraju MC, Kant V, Latief N, More AS, Kumar D et al. Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Neurochem Int. 2014; 68:1-9.

Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH et al.. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am.J.Physiol Heart Circ Physiol. 2006; 290:H1960-H1968.

Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology. 2010; 18:169-177.

Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb. 2010; 17:539-545.

Kesh SB, Sikder K, Manna K, Das DK, Khan A, Das N, Dey S. Promising role of ferulic acid, atorvastatin and their combination in ameliorating high fat diet-induced stress in mice. Life Sci. 2013; 92:938-949.

El-Abhar HS. Coenzyme Q10: a novel gastroprotective effect via modulation of vascular permeability, prostaglandin E(2), nitric oxide and redox status in indomethacin-induced gastric ulcer model. Eur J Pharmacol. 2010; 649:314-319.

Gomez-Hernandez A, Sanchez-Galan E, Ortego M, Martin-Ventura JL, Blanco-Colio LM, Tarin-Vicente N, Jimenez- Nacher JJ et al.. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2008; 102:12-18.

Reina S, Passafaro D, Sterin-Borda L, Borda E. Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjogren's syndrome. Inflammopharmacology. 2012; 20:267-275.

Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005; 65:345-355.

Taye A, El-Sheikh AA. Lectin-like oxidized low-density lipoprotein receptor 1 pathways. Eur J Clin Invest.

; 43:740-745.


Refbacks

  • There are currently no refbacks.